We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$601M
$150M 1.25%
14,808,585
+466,138
+3% +$5.42M
ISRG icon
27
Intuitive Surgical
ISRG
$127B
$146M 1.22%
2,711,700
-975,600
-26% -$54.6M
A icon
28
Agilent Technologies
A
$39.6B
$142M 1.18%
3,668,000
-383,000
-9% -$15.9M
TSRO
29
DELISTED
TESARO, Inc.
TSRO
$122M 1.02%
2,071,480
+13,780
+0.7% +$791K
TRNX
30
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$120M 1%
4,805,000
– –
RCPT
31
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$119M 1%
628,100
+472,000
+302% +$78M
ESRX
32
DELISTED
Express Scripts Holding Company
ESRX
$119M 1%
1,342,000
+9,000
+0.7% +$786K
PBYI icon
33
Puma Biotechnology
PBYI
$403M
$110M 0.92%
940,800
+570,600
+154% +$103M
AGN.PRA
34
DELISTED
Allergan plc
AGN.PRA
$109M 0.91%
+104,200
New +$109M
PFE icon
35
Pfizer
PFE
$143B
$102M 0.86%
3,217,862
+72,726
+2% +$2.37M
MGLN
36
DELISTED
Magellan Health Services, Inc.
MGLN
$102M 0.85%
1,450,700
+35,900
+3% +$2.44M
CYH icon
37
Community Health Systems
CYH
$385M
$96.3M 0.81%
+1,851,300
New +$83.1M
INSY
38
DELISTED
Insys Therapeutics, Inc.
INSY
$94.2M 0.79%
2,623,000
+136,600
+5% +$4.25M
MNK
39
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$93.6M 0.78%
795,000
+3,999
+0.5% +$493K
CLVS
40
DELISTED
Clovis Oncology, Inc.
CLVS
$88.3M 0.74%
1,005,200
+4,800
+0.5% +$411K
WMGI
41
DELISTED
Wright Medical Group Inc
WMGI
$87.6M 0.73%
3,337,000
+810,000
+32% +$21.4M
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$87.2M 0.73%
1,674,600
+6,000
+0.4% +$298K
GKOS icon
43
Glaukos
GKOS
$9.31B
$84M 0.7%
+2,897,937
New +$84.2M
AFFX
44
DELISTED
Affymetrix Inc
AFFX
$82M 0.69%
7,511,000
+160,000
+2% +$1.94M
ADAP
45
DELISTED
Adaptimmune Therapeutics
ADAP
$80.9M 0.68%
+4,411,186
New +$75.7M
SIEN
46
DELISTED
Sientra, Inc.
SIEN
$80.4M 0.67%
318,531
– –
AFMD
47
DELISTED
Affimed
AFMD
$78.3M 0.65%
581,463
– –
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
$72.5M 0.61%
10,060,500
+828,190
+9% +$6.11M
NUVA
49
DELISTED
NuVasive, Inc.
NUVA
$70.5M 0.59%
1,487,000
+415,000
+39% +$19.4M
JNJ icon
50
Johnson & Johnson
JNJ
$640B
$60.1M 0.5%
617,000
+4,000
+0.7% +$401K
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.